Literature DB >> 18187546

5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside reduces glucose uptake via the inhibition of Na+/H+ exchanger 1 in isolated rat ventricular cardiomyocytes.

Coralie Ségalen1, Sarah L Longnus, Delphine Baetz, Laurent Counillon, Emmanuel Van Obberghen.   

Abstract

AMP-activated protein kinase (AMPK) is an energy-sensing enzyme that is activated by an increased AMP/ATP ratio. AMPK is now well recognized to induce glucose uptake in skeletal muscle and heart. 5-Aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) is phosphorylated to form the AMP analog ZMP, which activates AMPK. Its effects on glucose transport appear to be tissue specific. The purpose of our study was to examine the effect of AICAR on insulin-induced glucose uptake in adult rat ventricular cardiomyocytes. We studied isolated adult rat ventricular cardiomyocytes treated or not with the AMPK activators AICAR and metformin and, subsequently, with insulin or not. Insulin action was investigated by determining deoxyglucose uptake, insulin receptor substrate-1- or -2-associated phosphatidylinositol 3-kinase activity and protein kinase B (PKB) cascade using antibodies to PKB, glycogen synthase kinase-3, and Akt substrate of 160 kDa. Intracellular pH was evaluated using the fluorescent pH-sensitive dye 2',7'-bis (2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF) and Na(+)/H(+) exchanger 1 (NHE1) activity was assessed using the NH(4)(+) prepulse method. Our key findings are as follows. AICAR and metformin enhance insulin signaling downstream of PKB. Metformin potentiates insulin-induced glucose uptake, but surprisingly, AICAR inhibits both basal and insulin-induced glucose uptake. Moreover, we found that AICAR decreases intracellular pH, via inhibition of NHE1. In conclusion, AMPK potentiates insulin signaling downstream of PKB in isolated cardiac myocytes, consistent with findings in the heart in vivo. Furthermore, AICAR inhibits basal and insulin-induced glucose uptake in isolated cardiac myocytes via the inhibition of NHE1 and the subsequent reduction of intracellular pH. Importantly, AICAR exerts these effects in a manner independent of AMPK activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187546     DOI: 10.1210/en.2007-1326

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  AICAR inhibits oxygen consumption by intact skeletal muscle cells in culture.

Authors:  Espen E Spangenburg; Kathryn C Jackson; Rosemary A Schuh
Journal:  J Physiol Biochem       Date:  2013-06-30       Impact factor: 4.158

2.  Chronic AICAR treatment prevents metabolic changes in cardiomyocytes exposed to free fatty acids.

Authors:  Christelle Viglino; Bernard Foglia; Christophe Montessuit
Journal:  Pflugers Arch       Date:  2019-05-31       Impact factor: 3.657

Review 3.  Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors.

Authors:  Milton Packer
Journal:  J Am Soc Nephrol       Date:  2020-04-10       Impact factor: 10.121

4.  Mimetics of hormetic agents: stress-resistance triggers.

Authors:  Joan Smith Sonneborn
Journal:  Dose Response       Date:  2010-01-06       Impact factor: 2.658

5.  Involvement of signaling molecules on na/h exchanger-1 activity in human monocytes.

Authors:  Maria Sarigianni; Apostolos Tsapas; Dimitri P Mikhailidis; Martha Kaloyianni; George Koliakos; Konstantinos Paletas
Journal:  Open Cardiovasc Med J       Date:  2010-09-28

6.  Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care.

Authors:  Milton Packer
Journal:  Eur Heart J       Date:  2020-07-01       Impact factor: 29.983

Review 7.  Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs.

Authors:  Milton Packer
Journal:  Cardiovasc Diabetol       Date:  2020-05-13       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.